CLOVER HEALTH INVESTMENTS, CORP. /DE Earnings Per Share Disclosure
| Year ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
(in thousands, except for per share and share amounts) | |||||||||||||||||
Numerator: | |||||||||||||||||
Net loss from continuing operations attributable to common stockholders | $ | (85,549) | $ | (46,266) | $ | (210,148) | |||||||||||
| Net income (loss) from discontinued operations attributable to common stockholders | — | 3,257 | (3,213) | ||||||||||||||
Denominator: | |||||||||||||||||
Weighted average number of common shares and common share equivalents outstanding, basic and diluted | 511,967,146 | 490,018,730 | 482,176,127 | ||||||||||||||
Basic and diluted loss per share from continuing operations | $ | (0.17) | $ | (0.09) | $ | (0.44) | |||||||||||
| Basic and diluted earnings (loss) per share from discontinued operations | $ | — | $ | 0.01 | $ | (0.01) | |||||||||||
| Year ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
Options to purchase common stock | 23,764,258 | 24,269,793 | 24,994,653 | ||||||||||||||
| RSUs | 42,953,954 | 55,731,587 | 56,928,405 | ||||||||||||||
| PRSUs | 27,523,030 | 29,151,407 | 32,131,532 | ||||||||||||||
Total potentially dilutive shares excluded from computation of net loss per share | 94,241,242 | 109,152,787 | 114,054,590 | ||||||||||||||
Want the next CLOVER HEALTH INVESTMENTS, CORP. /DE earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CLOVER HEALTH INVESTMENTS, CORP. /DE's next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.